CART22-65s cells

Phase 1Biologic

UUniversity of Pennsylvania

CART22-65s cells is one of 22 biologic programs targeting CAR. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CARActive, not recruiting

CARPhase 1

Active, not recruiting

Competition

Competitive Landscape

36 competitors in CAR

#DrugCompanyPhaseTrials

Isopto Carpine

AAdvanz Pharma

Phase 3

3 2

Floxin

WWim Janssens

Phase 3

1 3

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 4

Pelacarsen

Novartis

Phase 3

1 5

L-Carnitine

IIperboreal Pharma Srl

Phase 3

1 6

Tegretol

Novartis

Phase 1

10 7

Tylenol

KKenvue Brands

Phase 2

1 8

Verquvo

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 9

Diamox

Teva

Phase 1

2 10

Trileptal

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2036

Phase 1Active, not recruiting

CAR

NCT03620058

Clinical

Trials by Indication[1]

CAR1 trial

CART22 Alone or in Combination With huCART19 for ALL

Active, not recruiting·UUniversity of Pennsylvania·Phase 1·NCT03620058·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CART22-65s cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CART22-65s cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CART22-65s cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Pennsylvania company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Pennsylvania

CART22-65s cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2036

Trials by Indication[1]

CAR1 trial

References

Drug Info

Quick Facts

Related News